Reviewed by Lexie CornerJan 28 2025
Researchers from Jilin University have developed the Au-HN-1 nanosystem, a gold nanoparticle-based platform modified with HN-1 peptide, to target and treat tongue squamous cell carcinoma (TSCC). Published in the International Journal of Oral Science, the study highlights how this system enables precise cancer cell targeting, improving treatment specificity and efficacy for this aggressive cancer.
Illustration of the synthesis of Au-HN-1 and its application in tumor site imaging and PTT therapy. Image Credit: The authors
The Au-HN-1 nanosystem combines gold nanoparticles with HN-1 peptides, enabling enhanced photothermal therapy (PTT) and dual-mode imaging via fluorescence and computed tomography (CT). These capabilities support accurate tumor detection, surgical margin identification, and effective tumor ablation by localizing photosensitizers to tumor sites.
TSCC is a highly aggressive cancer characterized by significant metastasis and recurrence. Conventional treatments such as surgery, chemotherapy, and radiotherapy often lack specificity, leading to severe side effects, poor surgical outcomes due to imprecise tumor margin definition, and increased recurrence rates. The Au-HN-1 nanosystem addresses these challenges by improving precision and minimizing harm to healthy tissues.
In preclinical studies using mouse models, the nanosystem demonstrated selective targeting of TSCC cells, significantly enhancing the accumulation of photosensitizers at tumor sites. This improved the effectiveness of PTT by reducing tumor size while avoiding systemic toxicity. Dual-mode imaging further enabled precise tumor localization and margin delineation, which is crucial for improving surgical outcomes.
The Au-HN-1 system exhibits stability, biocompatibility, and minimal side effects, making it a promising platform for long-term in vivo imaging and personalized cancer therapy. By integrating diagnostic and therapeutic functions into a single system, this technology represents a significant advancement in cancer nanotechnology, offering precise tumor ablation and improved patient outcomes.
The Au-HN-1 nanosystem is a major step forward in TSCC treatment, as it integrates targeted therapy with dual-mode imaging. This combination enhances therapeutic precision while safeguarding healthy tissue, pushing the boundaries of what is possible in cancer nanotherapy.
Dr. Guoqing Wang, Study Lead Researcher, Jilin University
The nanosystem’s potential extends beyond TSCC. Its ability to enhance photothermal therapy, accurately ablate tumors, and identify tumor margins in real time could revolutionize surgical procedures. It also raises the possibility of treating other head and neck cancers, offering prospects for less invasive, more efficient therapies. Continued research to optimize the system may lead to more individualized and effective cancer treatments, improving patient outcomes and quality of life.
Journal Reference:
Hao, M., et al. (2025) Tongue squamous cell carcinoma-targeting Au-HN-1 nanosystem for CT imaging and photothermal therapy. International Journal of Oral Science. doi.org/10.1038/s41368-024-00343-7.